Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment ― Subanalysis of the J-Land II Study ―
Open Access
- 7 August 2020
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 2 (8), 440-445
- https://doi.org/10.1253/circrep.cr-20-0017
Abstract
Background:Post hoc analysis was used to investigate the effects of renal function on the efficacy and safety of landiolol using data from the J-Land II study, which evaluated landiolol in patients with hemodynamically unstable ventricular tachycardia (VT) or ventricular fibrillation (VF) who were refractory to Class III antiarrhythmic drugs. Methods and Results:Patient data from the J-Land II study (n=29) were stratified by renal function (estimated glomerular filtration rate [eGFR] 2) and analyzed. Continuous landiolol infusion (1 μg/kg/min, i.v.) was initiated after VT/VF was suppressed with electrical defibrillation; subsequent dose adjustments were made (1–40 μg/kg/min). The primary efficacy endpoint was the proportion of patients free from recurrent VT/VF during the assessment period. Safety endpoints were also assessed. In the eGFR 2groups, the median doses of landiolol during the assessment period were 9.44 and 8.97 μg/kg/min, the proportions of patients free from recurrent VT/VF were 69.2% and 81.8%, and adverse events occurred in 9 and 10 of 13 patients in each group, respectively. There were no apparent differences in the efficacy or safety of landiolol between the 2 groups. Conclusions:The data suggest that renal function may not affect the efficacy and safety of landiolol for hemodynamically unstable VT or VF.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy and Safety of the Ultra-Short-Acting β1-Selective Blocker Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhymias ― Outcomes of J-Land II Study ―Circulation Journal, 2019
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac DeathJournal of Invasive Cardiology, 2018
- Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceEuropean Heart Journal, 2018
- Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.Advances in Therapy, 2014
- Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter DefibrillatorAnnals of Noninvasive Electrocardiology, 2013
- Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular DysfunctionCirculation Journal, 2013
- Successful treatment of supraventricular tachyarrhythmias with landiolol during hemodialysis in a patient after receiving cardiac surgeryJournal of the Japanese Society of Intensive Care Medicine, 2010
- Impact of renal dysfunction on appropriate therapy in implantable cardioverter defibrillator patients with non-ischaemic dilated cardiomyopathyEP Europace, 2009
- Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal diseaseClinical Pharmacology & Therapeutics, 2003
- Intravenous Administration of Nifekalant Hydrochloride for the Prevention of Ischemia-Induced Ventricular Tachyarrhythmia in Patients With Renal Failure Undergoing HemodialysisCirculation Journal, 2003